机构:[a]School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, No. 280, East Ring Road, Higher Education Mega Center, Guangzhou 510006, China[b]The First Affiliated Hospital of Guangdong Pharmaceutical University, No. 19, Nong Lin Road, Yuexiu District, Guangzhou 510080, China[c]Guangzhou Baiyun Mountain Hutchison Whampoa Traditional Chinese Medicine Co., Ltd., Guangzhou 510515, China.
The intestinal barrier dysfunction is a critical pathological change in irritable bowel syndrome (IBS). The objective of this study was to evaluate the effect of Prim-O-glucosylcimifugin (POG) on intestinal barrier dysfunction and reveal possible molecular mechanisms. Human colon adenocarcinoma cell line (Caco-2) cell monolayers induced by tryptase (TRYP) were used to establish an intestinal barrier dysfunction model. Caco-2 cell monolayers from both functional and dysfunctional samples were treated with POG (30, 60 and 120 µg/mL) for 2, 8, 24, 36, 48 and 72 h. The Caco-2 cell monolayers were assessed by measurement of trans-epithelial electrical resistance (TEER) and percentage of fluorescein permeation (PFP). The expression of Protease Activated Receptor 2 (PAR-2) and myosin light chain kinase (MLCK) mRNA was analyzed by RT-PCR and the level of Zonula Occludens-1 (ZO-1) protein expression was determined by Western blot. In addition, the impact of POG on the distribution of the tight juction protein of Occludin was performed by immunofluorescence. Our results showed that POG elevated the TEER and decreased the PFP of the functional Caco-2 cell monolayers, as well as the dysfunctional Caco-2 cell monolayers. Furthermore, POG inhibited the expression of PAR-2 mRNA and MLCK mRNA and increased the level of ZO-1 protein expression in dysfunctional Caco-2 cells. The distribution of the Occludin proteins was ameliorated simultaneously. This study demonstrates that POG can enhance the intestinal barrier function of Caco-2 cell monolayers by inhibiting the expression of PAR-2 and MLCK and up-regulating the expression of ZO-1 protein, and ameliorated the distribution of Occludin protein.
基金:
This study was supported by the National
Natural Science Foundation of China (No. 81673620)
and the Joint Natural Sciences Fund of the Department of Science and Technology and the First Affiliated Hospital of
Guangdong Pharmaceutical University (No. GYFYLH201328).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|4 区医学
小类|4 区药学
最新[2025]版:
大类|4 区医学
小类|4 区药学
第一作者:
第一作者机构:[a]School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, No. 280, East Ring Road, Higher Education Mega Center, Guangzhou 510006, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Lu Xu,Jieyi Cai,Aofei Tian,et al.The Effect of Prim-O-Glucosylcimifugin on Tryptase-Induced Intestinal Barrier Dysfunction in Caco-2 Cells.[J].Biological & pharmaceutical bulletin.2018,41(9):1355-1361.doi:10.1248/bpb.b18-00059.
APA:
Lu Xu,Jieyi Cai,Aofei Tian,Kai Qian,Renan Qin...&Xuguang Hu.(2018).The Effect of Prim-O-Glucosylcimifugin on Tryptase-Induced Intestinal Barrier Dysfunction in Caco-2 Cells..Biological & pharmaceutical bulletin,41,(9)
MLA:
Lu Xu,et al."The Effect of Prim-O-Glucosylcimifugin on Tryptase-Induced Intestinal Barrier Dysfunction in Caco-2 Cells.".Biological & pharmaceutical bulletin 41..9(2018):1355-1361